Foresite Capital Fund III L.P. 13D and 13G filings for Aclaris Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-11 3:12 pm Sale |
2021-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
Foresite Capital Fund III L.P. | 4,657,277 7.600% |
-1,954,904 (-29.57%) |
Filing |
| 2021-02-11 2:56 pm Purchase |
2021-02-05 | 13G | Aclaris Therapeutics, Inc. ACRS |
Foresite Capital Fund III L.P. | 6,612,181 13.700% |
4,381,241 (+196.39%) |
Filing |
| 2020-10-26 7:47 pm Purchase |
2020-10-20 | 13G | Aclaris Therapeutics, Inc. ACRS |
Foresite Capital Fund III L.P. | 2,230,940 5.200% |
2,230,940 (New Position) |
Filing |